PsyPal, the first consortium to receive an EU clinical research grant for the study of psychedelic therapy, has published a comprehensive guidance paper to inform stakeholders across research, clinical practice, regulation, policy, advocacy, and industry. The paper outlines key considerations and actionable steps toward the standardisation and implementation of psychedelics in mental healthcare, addressing a critical gap between scientific progress and policy development.
In 2025, Norrsken Mind awarded grants totaling EUR 1.1 million (SEK 11.8 million) across eight psychedelic research and non-profit initiatives. The funded projects span clinical research examining the effects psilocybin, a comparative analysis of interventions for treatment-resistant depression, development of evidence assessment frameworks, research infrastructure in the Netherlands, and practitioner training in Ukraine, as well as policy work to explore early access to psychedelic therapies in the EU.
Norrsken Mind is funding the Independent Psychedelic Evidence Assessment Working Group (IPEA-WG) to develop new, rigorous and multidisciplinary standards for evaluating evidence related to psychedelic therapies. The project is led by Eduardo Schenberg, MSc, PhD (Faculty of Medicine, University of Lisbon), with co-chairs Franklin King, MD (Massachusetts General Hospital) and Marion Haberkamp, MD (German Federal Institute for Drugs and Medical Devices, BfArM).
PsyPal has reached a major milestone with the inclusion of its first patient in the multi-site clinical trial investigating psilocybin therapy for psychological and existential distress in people with progressive, life-limiting illnesses.
On September 16 in Malmö and September 17 in Stockholm, Norrsken Mind organizes two events focused on mental health and psychedelic therapy in Ukraine.
On September 26–27, 2025, the Borealis Psychedelic Science Summit will take place in Stockholm. Organized by the Swedish Network for Psychedelic Science, the conference is held at the Elite Hotel Marina Tower, bringing together researchers, clinicians, policymakers, and industry representatives worldwide. The event represents the first psychedelic science conference hosted in Sweden in seven years.
A comprehensive new report released today, funded by Norrsken Mind, maps the reimbursement landscape for psychedelic therapies across Europe, offering stakeholders an analytical look at the post-regulatory approval phase. While clinical research continues to highlight the therapeutic potential of psychedelics for conditions such as depression, PTSD, and addiction, this report zooms in on the critical challenge of securing sustainable market access and reimbursement.
The PsyPal consortium ("Consortium") is proud to announce that the clinical trial PsyPal has been authorised according to the Clinical Trials Regulation (CTR) in the participating member states, with conditions.
.png)
